We’re getting there very quickly. One of the big questions is, “How do these research findings translate, as you say, to treatment for patients?” We can find what’s driving a particular cancer, but the question is, “Will the treatment directed at that particular change in the DNA actually affect the outcomes of patients?” We’re getting more and more data that, in fact, that knowledge is directly transferable across different tumors to the outcome of patients. The research is translating actually quite well to patient benefit as we go forward.
